(FN) Fabrinet - Overview
Stock: Optical Components, Transceivers, Lasers, Sensors, Glass Products
| Risk 5d forecast | |
|---|---|
| Volatility | 78.2% |
| Relative Tail Risk | -11.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.53 |
| Alpha | 92.06 |
| Character TTM | |
|---|---|
| Beta | 1.904 |
| Beta Downside | 1.685 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.47% |
| CAGR/Max DD | 1.47 |
EPS (Earnings per Share)
Revenue
Description: FN Fabrinet January 04, 2026
Fabrinet (NYSE:FN) is a contract manufacturer that specializes in optical packaging and precision electro-mechanical and electronic services across North America, APAC, and Europe. Its end-to-end capabilities span process design, supply-chain management, PCB assembly, integration, final testing, and high-volume production of complex optical components.
The product portfolio includes reconfigurable optical add-drop multiplexers (ROADMs), optical amplifiers, modulators, transceivers, tunable lasers, and active optical cables that support high-speed interconnects for data-center and computing-cluster applications (e.g., Infiniband, Ethernet, Fibre Channel). Fabrinet also produces a range of lasers (solid-state, diode-pumped, gas, fiber) for semiconductor, biotech, and metrology markets, as well as sensors (differential pressure, micro-gyro, fuel) for automotive and medical devices, and custom optical glass components (crystals, lenses, prisms, fused silica).
Key financial and market metrics (FY 2023): revenue of roughly **$1.3 billion**, an adjusted EBITDA margin of **~8 %**, and a **~12 %** year-over-year growth rate driven largely by rising data-center demand and 5G infrastructure roll-outs. The EMS sector is currently benefitting from a **global telecom-capex surge** (estimated $1.2 trillion in 2024) and a **tight supply of advanced optical components**, which together create a favorable tailwind for Fabrinet’s high-mix, high-value contracts.
Fabrinet’s customer base is diversified across OEMs of optical communication modules, industrial lasers, automotive sensors, and medical devices, reducing reliance on any single end-market. However, the company remains exposed to **cyclical semiconductor and telecom spending**, and to **geopolitical supply-chain risks** in the Asia-Pacific region.
For a deeper dive into FN’s valuation metrics and peer comparison, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income: 374.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -9.24 > 1.0 |
| NWC/Revenue: 44.63% < 20% (prev 49.18%; Δ -4.56% < -1%) |
| CFO/TA 0.09 > 3% & CFO 278.1m > Net Income 374.1m |
| Net Debt (-311.8m) to EBITDA (458.0m): -0.68 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (36.2m) vs 12m ago -0.62% < -2% |
| Gross Margin: 12.01% > 18% (prev 0.12%; Δ 1189 % > 0.5%) |
| Asset Turnover: 134.0% > 50% (prev 122.8%; Δ 11.15% > 0%) |
| Interest Coverage Ratio: -100.0k > 6 (EBITDA TTM 458.0m / Interest Expense TTM -1.0) |
Altman Z'' 8.95
| A: 0.53 (Total Current Assets 2.77b - Total Current Liabilities 1.04b) / Total Assets 3.27b |
| B: 0.70 (Retained Earnings 2.30b / Total Assets 3.27b) |
| C: 0.14 (EBIT TTM 400.7m / Avg Total Assets 2.91b) |
| D: 2.14 (Book Value of Equity 2.32b / Total Liabilities 1.08b) |
| Altman-Z'' Score: 8.95 = AAA |
Beneish M -2.41
| DSRI: 0.95 (Receivables 801.7m/680.1m, Revenue 3.89b/3.12b) |
| GMI: 1.02 (GM 12.01% / 12.27%) |
| AQI: 1.73 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.25 (Revenue 3.89b / 3.12b) |
| TATA: 0.03 (NI 374.1m - CFO 278.1m) / TA 3.27b) |
| Beneish M-Score: -2.41 (Cap -4..+1) = BBB |
What is the price of FN shares?
Over the past week, the price has changed by +3.96%, over one month by +0.72%, over three months by -0.20% and over the past year by +121.11%.
Is FN a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 517.4 | 11% |
| Analysts Target Price | 517.4 | 11% |
| ValueRay Target Price | 700.2 | 50.2% |
FN Fundamental Data Overview February 07, 2026
P/S = 4.0747
P/B = 6.9368
P/EG = 1.19
Revenue TTM = 3.89b USD
EBIT TTM = 400.7m USD
EBITDA TTM = 458.0m USD
Long Term Debt = 5.47m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 1.69m USD (from shortTermDebt, last quarter)
Debt = 8.08m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -311.8m USD (from netDebt column, last quarter)
Enterprise Value = 15.86b USD (15.86b + Debt 8.08m - CCE 11.5m)
Interest Coverage Ratio = -400.7m (Ebit TTM 400.7m / Interest Expense TTM -1.0)
EV/FCF = 155.8x (Enterprise Value 15.86b / FCF TTM 101.8m)
FCF Yield = 0.64% (FCF TTM 101.8m / Enterprise Value 15.86b)
FCF Margin = 2.62% (FCF TTM 101.8m / Revenue TTM 3.89b)
Net Margin = 9.61% (Net Income TTM 374.1m / Revenue TTM 3.89b)
Gross Margin = 12.01% ((Revenue TTM 3.89b - Cost of Revenue TTM 3.42b) / Revenue TTM)
Gross Margin QoQ = 12.15% (prev 11.90%)
Tobins Q-Ratio = 4.85 (Enterprise Value 15.86b / Total Assets 3.27b)
Interest Expense / Debt = -0.00% (Interest Expense -1.0 / Debt 8.08m)
Taxrate = 5.93% (7.10m / 119.7m)
NOPAT = 376.9m (EBIT 400.7m * (1 - 5.93%))
Current Ratio = 2.68 (Total Current Assets 2.77b / Total Current Liabilities 1.04b)
Debt / Equity = 0.00 (Debt 8.08m / totalStockholderEquity, last quarter 2.18b)
Debt / EBITDA = -0.68 (Net Debt -311.8m / EBITDA 458.0m)
Debt / FCF = -3.06 (Net Debt -311.8m / FCF TTM 101.8m)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.88% (Net Income 374.1m / Total Assets 3.27b)
RoE = 18.39% (Net Income TTM 374.1m / Total Stockholder Equity 2.03b)
RoCE = 19.65% (EBIT 400.7m / Capital Employed (Equity 2.03b + L.T.Debt 5.47m))
RoIC = 19.00% (NOPAT 376.9m / Invested Capital 1.98b)
WACC = 12.92% (E(15.86b)/V(15.87b) * Re(12.93%) + D(8.08m)/V(15.87b) * Rd(-0.00%) * (1-Tc(0.06)))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.64%
[DCF Debug] Terminal Value 66.93% ; FCFF base≈186.8m ; Y1≈230.4m ; Y5≈392.4m
Fair Price DCF = 100.2 (EV 3.28b - Net Debt -311.8m = Equity 3.59b / Shares 35.8m; r=12.92% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 93.72 | EPS CAGR: 23.99% | SUE: 0.70 | # QB: 0
Revenue Correlation: 96.83 | Revenue CAGR: 20.42% | SUE: 4.0 | # QB: 5
EPS next Quarter (2026-03-31): EPS=3.55 | Chg30d=+0.093 | Revisions Net=+7 | Analysts=8
EPS current Year (2026-06-30): EPS=13.58 | Chg30d=+0.299 | Revisions Net=+7 | Growth EPS=+33.5% | Growth Revenue=+32.7%
EPS next Year (2027-06-30): EPS=15.85 | Chg30d=+0.543 | Revisions Net=+5 | Growth EPS=+16.7% | Growth Revenue=+15.3%